enow.com Web Search

  1. Ads

    related to: fast acting insulin

Search results

  1. Results from the WOW.Com Content Network
  2. Insulin (medication) - Wikipedia

    en.wikipedia.org/wiki/Insulin_(medication)

    The long acting insulin is given once (usually glargine, Lantus) or twice (usually detemir, Levemir) daily to provide a base, or basal insulin level. Rapid acting (RA) insulin is given before meals and snacks. A similar profile can be provided using an insulin pump where rapid acting insulin is given as the basal and premeal bolus insulin.

  3. Insulin analog - Wikipedia

    en.wikipedia.org/wiki/Insulin_analog

    Glulisine is rapid acting insulin analog from Sanofi-Aventis, approved for use with a regular syringe, in an insulin pump. Standard syringe delivery is also an option. It is sold under the name Apidra. The FDA-approved label states that it differs from regular human insulin by its rapid onset and shorter duration of action. [3]

  4. Insulin aspart - Wikipedia

    en.wikipedia.org/wiki/Insulin_aspart

    The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. [14] The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. [27]

  5. Fast-acting, inhaled insulin Afrezza approved by F.D.A. - AOL

    www.aol.com/article/2014/06/29/fast-acting...

    The U.S. Food and Drug Administration has approved a fast-acting diabetes drug called Afrezza for use by adults with Type 1 or Type 2 diabetes. The drug is inhaled into the lungs using a small ...

  6. Insulin tregopil - Wikipedia

    en.wikipedia.org/wiki/Insulin_tregopil

    Insulin tregopil; Clinical data; Other names: IN-105: Legal status; ... Identifiers; CAS Number: 874442-57-6; UNII: 3UYC0OZ5ON; Insulin tregopil is a fast-acting ...

  7. 5 Companies Dominating Diabetes - AOL

    www.aol.com/news/2012-11-06-5-companies...

    There are estimates that revenues could exceed $20 billion by 2018. Novo's product portfolio includes the fast-acting insulin analog pen NovoLog and the long-acting injection Levemir.

  1. Ads

    related to: fast acting insulin